The environmental impact of healthcare has become an increasing focus of policy and research, with anesthetic gases identified as a measurable contributor to greenhouse gas emissions. Among volatile anesthetics, desflurane has emerged as a particular concern because of its exceptionally high global warming potential. In response to growing evidence and international climate commitments, the European Union (EU) has introduced new regulations that significantly restrict the use of desflurane.
Desflurane has long been valued in clinical anesthesia for its low blood–gas solubility, which allows for rapid induction and emergence. Despite these advantages, its environmental footprint is substantial. Desflurane has a global warming potential many times greater than that of carbon dioxide and markedly higher than other commonly used volatile anesthetics, such as sevoflurane and isoflurane.
In 2023, the European Parliament approved revisions to the EU Fluorinated Greenhouse Gases (F-gases) Regulation as part of the European Green Deal. Routine use of desflurane as an inhalational anesthetic will be prohibited across EU member states beginning January 1, 2026. Continued use will be permitted only in exceptional clinical circumstances where no suitable alternative is available.
The medical literature supports this policy direction. Comparative studies have shown that replacing desflurane with agents such as sevoflurane or using total intravenous anesthesia can substantially reduce the carbon footprint of anesthesia without compromising patient safety or perioperative outcomes.
These regulations represent an important step toward environmentally sustainable healthcare while maintaining high standards of patient care.